ACAD
47.56
-1.19
-2.44%
AEMD
10
-1.38
-12.13%
APRI
1.52
-0.07
-4.40%
ARNA
3.99
-0.06
-1.48%
ATEC
1.37
+0.01
+0.74%
CNAT
4.9
-0.17
-3.35%
CRXM
0.295
0.00
0.00%
CYTX
0.4
-0.005
-1.3317%
DXCM
81.7
-1.39
-1.67%
GNMK
9.1
-0.66
-6.76%
HALO
22.8
-0.44
-1.89%
ILMN
217.27
-3.83
-1.73%
INNV
0.158
+0.008
+5.333%
INO
7.18
+0.12
+1.70%
ISCO
0.048
+0.004
+9.9537%
ISIS
53.68
+0.53
+1.00%
LGND
102.55
+0.46
+0.45%
LPTN
0.28
-0.02
-6.98%
MBVX
1.6
-0.19
-10.61%
MEIP
1.55
-0.06
-3.73%
MNOV
3.81
+0.3
+8.55%
MRTX
28.24
-0.48
-1.67%
MSTX
0.468
-0.002
-0.5106%
NBIX
49.34
-2.16
-4.19%
NUVA
49.59
+0.08
+0.16%
ONCS
6.03
-0.32
-5.04%
ONVO
3.38
-0.09
-2.59%
OREX
4.21
+0.02
+0.48%
OTIC
26.98
+0.32
+1.20%
QDEL
22.39
-0.5
-2.18%
RCPT
227.09
-0.91
-0.40%
RGLS
8.68
-0.49
-5.34%
RMD
55.17
-0.75
-1.34%
SCIE
0.019
-0.004
-16.300%
SPHS
0.86
+0.08
+10.26%
SRNE
23.7
+0.19
+0.81%
TROV
8.52
-0.28
-3.18%
VICL
0.61
-0.01
-2.40%
ZGNX
19.87
-0.4
-1.97%
ACAD
47.56
-1.19
-2.44%
AEMD
10
-1.38
-12.13%
APRI
1.52
-0.07
-4.40%
ARNA
3.99
-0.06
-1.48%
ATEC
1.37
+0.01
+0.74%
CNAT
4.9
-0.17
-3.35%
CRXM
0.295
0.00
0.00%
CYTX
0.4
-0.005
-1.3317%
DXCM
81.7
-1.39
-1.67%
GNMK
9.1
-0.66
-6.76%
HALO
22.8
-0.44
-1.89%
ILMN
217.27
-3.83
-1.73%
INNV
0.158
+0.008
+5.333%
INO
7.18
+0.12
+1.70%
ISCO
0.048
+0.004
+9.9537%
ISIS
53.68
+0.53
+1.00%
LGND
102.55
+0.46
+0.45%
LPTN
0.28
-0.02
-6.98%
MBVX
1.6
-0.19
-10.61%
MEIP
1.55
-0.06
-3.73%
MNOV
3.81
+0.3
+8.55%
MRTX
28.24
-0.48
-1.67%
MSTX
0.468
-0.002
-0.5106%
NBIX
49.34
-2.16
-4.19%
NUVA
49.59
+0.08
+0.16%
ONCS
6.03
-0.32
-5.04%
ONVO
3.38
-0.09
-2.59%
OREX
4.21
+0.02
+0.48%
OTIC
26.98
+0.32
+1.20%
QDEL
22.39
-0.5
-2.18%
RCPT
227.09
-0.91
-0.40%
RGLS
8.68
-0.49
-5.34%
RMD
55.17
-0.75
-1.34%
SCIE
0.019
-0.004
-16.300%
SPHS
0.86
+0.08
+10.26%
SRNE
23.7
+0.19
+0.81%
TROV
8.52
-0.28
-3.18%
VICL
0.61
-0.01
-2.40%
ZGNX
19.87
-0.4
-1.97%
Home » Bio: Joseph E. Payne

Bio: Joseph E. Payne

Joseph E. Payne brings with him an exceptional track record of ushering novel therapeutics to the clinic including successful experience developing sophisticated targeted RNAi nanoparticle technologies.  Joseph’s background includes over 20 years of successful drug discovery experience at Merck Research Labs, DuPont Pharmaceuticals, Bristol-Myers Squibb, Kalypsys, and Nitto Denko as evidenced by over 40 publications and patents, and 7 FDA-approved IND clinical candidates.  His academic training includes BYU (magna cum laude, Chemistry and Physics), University of Calgary (Synthetic Organic Chemistry), and MIT Sloan School of Management (Executive Training, Supply Chain and Logistics.